Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma

Phase 1/2 Completed 55 enrolled Pharmacyclics LLC.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The first part of the study will determine the highest dose of study drug that can be taken without causing serious side effects in patients with lymphoma. The appropriate dose determined from the first part of the study will be used in the second part of the study to assess disease response in 2 different types of lymphoma patients.

Timeline

Start: 2008-07
Primary completion: 2012-11
Completion: —

Publications

Results Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, Schultz BE, Young PR, Dalrymple SA. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther. 2006 May;5(5):1309-17. doi: 10.1158/1535-7163.MCT-05-0442.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abexinostat	Small molecule	30 mg/m2	Oral
Subject	Abexinostat	Small molecule	90 mg/m2	Oral

Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma

Summary

Timeline

Publications

Drugs

Indications